Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Lorlatinib in ALK/ROS1-positive Advanced NSCLC
jRCT2080222982Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of lorlatinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer (NSCLC) (2 arms), sponsored by Pfizer. Primary endpoints: Safety and tolerability of lorlatinib and Antitumor activity of lorlatinib. Started Oct 2015; status: completed.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080222982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222982.